Effects of simvastatin and 6-hydroxydopamine on histaminergic H1 receptor binding density in rat brains

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 8, 2010, Pages 1419-1425

  Hu, Chang Hua ^a,c   Deng, Chao ^a   Mackovski, Nikolce ^a   Long, Ling ^b   Zhu, Cansheng ^b   Yang, Yu ^b   Wang, Yuge ^b   Chen, Jiezhong ^a   Huang, Xu Feng ^a   Wang, Qing ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SUN YAT SEN UNIVERSITY   (China)

^c SOUTHWEST UNIVERSITY   (China)

Author keywords

6 Hydroxydopamine; Histamine; Receptor; Simvastatin

Indexed keywords

HISTAMINE H1 RECEPTOR; OXIDOPAMINE; SIMVASTATIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING KINETICS; CINGULATE GYRUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HIPPOCAMPUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; MALE; MOTOR CORTEX; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PREFRONTAL CORTEX; PUTAMEN; RAT; RECEPTOR BINDING;

ANIMALS; BRAIN; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, HISTAMINE H1; SIMVASTATIN;

EID: 78649518546     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.025     Document Type: Article

References (41)

1. Anichtchik O.V., Peitsaro N., Rinne J.O., Kalimo H., Panula P. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Dis 2001, 8(4):707-716.
2. Anichtchik O.V., Rinne J.O., Kalimo H., Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp Neurol 2000, 163(1):20-30.
3. Barbara A., Aceves J., Arias-Montano J.A. Histamine H1 receptors in rat dorsal raphe nucleus: pharmacological characterisation and linking to increased neuronal activity. Brain Res 2002, 954(2):247-255.
4. De Esch I.J., Thurmond R.L., Jongejan A., Leurs R. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005, 26:462-469.
5. Deng C., Huang X.-F. Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Exp Brain Res 2006, 168(4):587-590.
6. Deng C., Weston-Green K., Huang X.-F. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog Neuro Psychopharmacol Biol Psychiatry 2010, 34(1):1-4.
7. Ghosh A., Roy A., Matras J., Brahmachari S., Gendelman H.E., Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 2009, 29(43):13543-13556.
8. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the nervous system. Physiol Rev 2008, 88(3):1183-1241.
9. Han M., Deng C., Burne T.H.J., Newell K.A., Huang X.-F. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 2008, 33(5):569-580.
10. Haq A.U., Bundrant H.M., Mercer L.P. Food intake is inversely correlated with central nervous system histamine receptor (H1) concentrations in male Sprague-Dawley rats fed normal, low protein, low energy or poor quality protein diets. J Nutr 1996, 126(12):3083-3089.
11. Hernández-Romero M.C., Argüelles S., Villarán R.F., et al. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J Neurochem 2008, 105(2):445-459.
12. Huang X.-F., Yu Y., Li Y., Tim S., Deng C., Wang Q. Ventromedial hypothalamic NPY Y2 receptor in the maintenance of body weight in diet-induced obesity in mice. Neurochem Res 2008, 33(9):1881-1888.
13. Iinuma K., Yokoyama H., Otsuki T., et al. Histamine H1 receptors in complex partial seizures. Lancet 1993, 341(8839):238.
14. Iwabuchi K., Ito C., Tashiro M., et al. Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. Eur Neuropsychopharmacol 2005, 15(2):185-191.
15. Jin C.Y., Panula P. The laminar histamine receptor system in human prefrontal cortex suggests multiple levels of histaminergic regulation. Neuroscience 2005, 132(1):137-149.
16. Kroeze W.K., Hufeisen S.J., Popadak B.A., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28(3):519-526.
17. Li Y., Huang X.F., Deng C., et al. Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats. Synapse 2010, 64(3):224-230.
18. Magrani J., de Castroe Silva E., Varjão B., et al. Histaminergic H1 and H2 receptors located within the ventromedial hypothalamus regulate food and water intake in rats. Pharmacol Biochem Behav 2004, 79(1):189-198.
19. Martinez-Mir M.I., Pollard H., Moreau J., et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and nonhuman primates. Brain Res 1990, 526:322-327.
20. Masaki T., Chilba S., Yasuda T., et al. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004, 53(9):2250-2260.
21. Matsui-Sakata A., Ohtani H., Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005, 20(5):368-378.
22. Mercer L.P., Kelley D.S., Humphries L.L., Dunn J.D. Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats. J Nutr 1994, 124(7):1029-1036.
23. Miyoshi K., Kawakami N., Wakayama Y., Izumi N., Horio S., Fukui H. Histamine H1 receptor down-regulation mediated by M3 muscarinic acetylcholine receptor subtype. J Pharmacol Sci 2004, 95(4):426-434.
24. Nowak P., Dabrowska J., Bortel A., et al. Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-lesioned rats occurs in an absence of change in microdialysate dopamine levels. Eur J Pharmacol 2006, 552(1-3):46-54.
25. Palacios J.M., Wamsley J.K., Kuhar M.J. The distribution of histamine H1-receptors in the rat brain: an autoradiographic study. Neuroscience 1981, 6(1):15-37.
26. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic Press, San Diego.
27. Roglans N., Verd J.C., Peris C., et al. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 2002, 37(5):445-454.
28. Ryu J.H., Yanai K., Sakurai E., Kim C.-Y., Watanabe T. Ontogenetic development of histamine receptor subtypes in rat brain demonstrated by quantitative autoradiography. Dev Brain Res 1995, 87(2):101-110.
29. Schoonjans K., Peinado-Onsurbe J., Fruchart J.C., Tailleux A., Fiévet C., Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 1999, 452(3):160-164.
30. Schuster S., Nadjar A., Guo J.T., et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci 2008, 28(17):4311-4316.
31. Selley M.L. Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005, 1037(1-2):1-6.
32. Tran V.T., Chang R.S., Snyder S.H. Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine. Proc Natl Acad Sci USA 1978, 75(12):6290-6294.
33. Wang Q., Huang X.f. Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain. Exp Neurol 2008, 209(1):261-267.
34. Wang Q., Ting W.L., Yang H., Wong P.T. High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br J Pharmacol 2005, 144(7):933-939.
35. Wang Q., Wang P.H., McLachlan C., Wong P.T. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res 2005, 1045(1-2):229-233.
36. Wang Q, Yan, J., Chen, X., Li, J., Yang, Y., Weng, J., Deng, C., Yenari, M.A. 2010. Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol In press.
37. Wang Q., Zengin A., Deng C., et al. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol 2009, 216(1):132-138.
38. Wang Q., Zengin A., Ying W., et al. Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain. Neuroscience 2008, 154(3):1100-1106.
39. Yoshimatsu H. The neuronal histamine H1 and pro-opiomelanocortin-melanocortin 4 receptors: independent regulation of food intake and energy expenditure. Peptides 2006, 27(2):326-332.
40. Yoshizawa M., Tashiro M., Fukudo S., et al. Increased brain histamine H1 receptor binding in patients with anorexia nervosa. Biol Psychiatry 2009, 65(4):329-335.
41. Yuan H., Sarre S., Ebinger G., Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Meth 2005, 144(1):35-45.